Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Lung Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 29Carboplatin 27durvalumab 21Specimen Handling 21Pemetrexed 18Cisplatin 17Paclitaxel 16atezolizumab 15Nivolumab 15Magnetic Resonance Spectroscopy 15osimertinib 11Radiosurgery 11Radiotherapy 10Immunoglobulin G 10Etoposide 10Docetaxel 10Disulfides 10Radiation 9Taxes 8Gemcitabine 8Biopsy 8Blood Specimen Collection 7Standard of Care 6Practice Guidelines as Topic 6Ipilimumab 6Surveys and Questionnaires 5Platinum 5Bronchoscopy 5Bevacizumab 5Ramucirumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lung Neoplasms × CIMAvax EGF × Clear all
NCT02955290 2025-11-10

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
51 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡